NCT01446926View on ClinicalTrials.gov

Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2013

Conditions
PneumoniaPneumococcal InfectionsStreptococcus Pneumoniae Infections
Interventions
BIOLOGICAL

Pneumococcal Vaccine High Dose (Formulation 1)

0.5 mL, Intramuscular

BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

BIOLOGICAL

Pneumococcal Vaccine High Dose (Formulation 1)

0.5 mL, Intramuscular

BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

BIOLOGICAL

Pneumococcal Vaccine Low Dose (Formulation 2)

0.5 mL, Intramuscular

BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

BIOLOGICAL

Pneumococcal Vaccine Middle Dose (Formulation 3)

0.5 mL, Intramuscular

BIOLOGICAL

Pneumococcal Vaccine Middle Dose (Formulation 4)

0.5 mL, Intramuscular

BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

BIOLOGICAL

Pneumococcal Vaccine High Dose (Formulation 1)

0.5 mL, Intramuscular

BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

Trial Locations (1)

1212

Dhaka

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants | Biotech Hunter | Biotech Hunter